**Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science**

**Author affiliations and qualifications**

Department of Psychology, Uppsala University, Uppsala, Sweden (Prof E A Holmes PhD)

Suicidal Behaviour Research Laboratory, Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK (Prof R C O’Connor PhD)

UK Dementia Research Institute (Prof V H Perry PhD), Centre for Behaviour Change (Prof S Michie PhD), UCL Great Ormond Street Institute of Child Health (Prof R Shafran PhD), University College London, London, UK

Nuffield Department of Clinical Neurosciences (Prof I Tracey PhD), Oxford Internet Institute (Prof A K Przybylski PhD), University of Oxford, Oxford, UK

Institute of Psychiatry, Psychology and Neuroscience (Prof L Arseneault PhD, Prof I Everall PhD, Prof M Hotopf PhD and Prof S Wessely PhD), Medicine Clinical Academic Group (Prof I Madan PhD), King’s College London, London, UK

University of Exeter Medical School, University of Exeter, Exeter, UK (Prof C Ballard PhD)

Black Dog Institute, Sydney, Australia (Prof H Christensen PhD)

Department of Psychological Science, University of California, Irvine, USA (Prof R Cohen Silver PhD)

Department of Psychiatry (Prof T Ford PhD and Prof E Bullmore PhD), University of Cambridge, Cambridge, UK

Swansea University Medical School, Swansea University, Swansea, UK (Prof A John PhD)

The McPin Foundation, London, UK (T Kabir PhD)

Independent, UK (K King)

Population Health Research Institute, St George's University of London, London, UK (A Sweeney PhD)

Anthropology Faculty, Emory University, Atlanta, USA (Prof C M Worthman PhD)

School of Psychological Science, University of Bristol, Bristol, UK (Prof L Yardley PhD)

Katherine Cowan Consulting Limited, UK (K Cowan MA)

Academy of Medical Sciences, London, UK (C Cope PhD)

**Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science**

Emily A. Holmes\*, Rory C. O’Connor\*, V Hugh Perry, Irene Tracey, Simon Wessely, Louise Arseneault, Clive Ballard, Helen Christensen, Roxane Cohen Silver, Ian Everall, Tamsin Ford, Ann John, Thomas Kabir, Kate King, Ira Madan, Susan Michie, Andrew K. Przybylski, Roz Shafran, Angela Sweeney, Carol M. Worthman, Lucy Yardley, Katherine Cowan, Claire Cope$, Matthew Hotopf#, Ed Bullmore#

\* Joint first authors

# Joint last authors

$ Corresponding author: Dr Claire Cope, Academy of Medical Sciences, 41 Portland Place, London W1B 1QH (email: [claire.cope@acmedsci.ac.uk](mailto:claire.cope@acmedsci.ac.uk); tel: +44 (0) 7842 903 249)

**Abstract**

The COVID-19 pandemic is having a profound effect on all aspects of society, including mental health as well as physical health. We explore the psychological, social and neuroscience impacts of COVID-19, and set out immediate priorities and longer-term strategies for mental health science research. These priorities were informed by surveys of the public and an expert panel convened by the UK Academy of Medical Sciences and the mental health research charity, MQ: Transforming Mental Health, in the first weeks of the pandemic in the UK in March 2020. We urge UK research funding agencies to work with researchers, people with lived experience and others to establish a high level co-ordination group to ensure that these research priorities are addressed, and to allow new ones to be identified over time. The need to maintain high quality research standards is imperative. International collaboration and a global perspective will be beneficial. An immediate priority is collecting data on the mental health impacts of the COVID-19 pandemic across the whole population and vulnerable groups, and on brain function, cognition and mental health for COVID-19 patients. There is an urgent need for research to address how mental health consequences for vulnerable groups can be mitigated under pandemic conditions, as well as on the impact of repeated media consumption and health messaging around COVID-19. Discovery, evaluation and refinement of mechanistically-driven interventions to address the psychological, social and neuroscientific aspects of this pandemic are required. Rising to this challenge will require integration across disciplines and sectors, and should be done together with people with lived experience. New funding will be required to meet these priorities, but it can be efficiently leveraged by the UK’s world-leading infrastructure.

**1. Introduction**

It is already evident that the direct and indirect psychological and social impacts of the pandemic are pervasive, and could affect mental health now and into the future. The pandemic is occurring against the backdrop of increased prevalence of mental health issues in the UK in recent years in some groups1,2. Furthermore, SARS-CoV2, the virus causing COVID-19, might infect the brain or trigger immune responses that have additional adverse effects on brain function and mental health in COVID-19 patients.

Research funders and researchers must deploy resources to understand the psychological, social and biological impacts of the COVID-19 pandemic. Mobilisation now will allow us to apply the learnings gained to any future periods of increased infection and lockdown, which will be particularly important for frontline workers, and for vulnerable groups. We propose a framework for the prioritization and coordination of essential, policy-relevant psychological, social and neuroscience research, to ensure that any investment is efficiently targeted on the critical mental health science questions as the pandemic unfolds. We use the term ‘mental health sciences’ to reflect the many different disciplines, including but not limited to psychology, psychiatry, clinical medicine, behavioural and social sciences and neuroscience, that will need to work together in a multidisciplinary fashion together with people with lived experience to address these research priorities.

The UK has powerful advantages in mounting a successful response to the pandemic, including strong existing research infrastructure and expertise, but the community must act rapidly and collaboratively if it is to deal with the growing threats to mental health. A fragmented research response, characterized by small-scale and localized initiatives, will not yield the clear insights necessary to guide policy-makers or the public. Rigorous scientific and ethical review of protocols and results remains the cornerstone of safeguarding participants and upholding research standards. Deploying a mental health science perspective3 to the pandemic will also inform population-level behaviour change initiatives aimed at reducing the spread of the virus. International comparisons will be especially helpful in this regard. In this paper, we explore the psychological, social and neuroscience impacts of COVID-19, and set out clear, immediate priorities and longer-term strategies for each of these aspects.

We also conducted surveys of the public and people with lived experience of mental ill-health. The general population survey, conducted by Ipsos MORI, revealed widespread concerns about the impact of social isolation or social distancing on wellbeing; increased levels of anxiety, depression, stress and other negative feelings; and concern about the practical implications of pandemic response including financial difficulties. The prospect of becoming physically unwell with COVID-19 ranked lower than these issues related to the social response to the pandemic. The MQ stakeholder survey of people with lived experience of a mental health issue likewise highlighted general concerns about social isolation and increased levels of anxiety and depression. More specifically, stakeholders frequently expressed concerns about exacerbation of pre-existing mental health issues, greater difficulty in accessing mental health support and services under pandemic conditions, and impact of COVID-19 on the mental health of family members, especially children and older people. Both surveys are reported in full in the web appendix. These findings, combined with the published scientific literature, informed the development of our research priorities. They represent a snapshot of the current situation, but will need to be repeated more rigorously over the course of the pandemic.

**Panel 1: Methodology**

This article summarises the priorities put forward by an interdisciplinary group of 24 world-leading experts, including people with lived experience, from across the bio-psycho-social spectrum of expertise in mental health science in March/April 2020. The experts were convened by the UK Academy of Medical Sciences and the mental health research charity, MQ: Transforming Mental Health. Members participated in an individual capacity, not as representatives of their organisations. A coordinating group of seven experts met daily over a period of two weeks to develop the research priorities, informed by input from the expert advisory group. Given the need to develop the research priorities rapidly to inform immediate funding priorities, extended evidence gathering and consultation was not possible. However, we are confident that the wide breadth of expertise on the expert group and their leading roles in their respective fields provide a wide-ranging and comprehensive view of the mental health and neuroscience research priorities.

Lived experience was incorporated by four mechanisms. First, three lived experience representatives provided input via the expert advisory group. Second, an online survey collected data on people’s two biggest concerns about the mental health and wellbeing implications of the COVID-19 pandemic, as well as coping strategies. The survey was promoted via email to MQ’s supporter network as well as via social media. In total, 2,198 people completed the survey, submitting 4,350 concerns about the mental health impacts of the COVID-19 pandemic and 1,987 responses about what has helped maintain mental health and wellbeing during the pandemic. A thematic analysis of the full dataset was carried out. Third, two questions were asked on Ipsos MORI’s online Omnibus survey to collect data on people’s concerns about the impact of COVID-19 on mental wellbeing, as well as what is helping people’s mental wellbeing at this time. In total, 1,099 interviews were completed with adults aged between 16 and 75 across England, Wales and Scotland. Quotas were set and data were weighted to the offline population to ensure a nationally representative sample by gender, age and region. Statistical analysis was carried out and any sub-group differences included are statistically significant at a 95% confidence interval unless stated otherwise. A summary report of the findings of both surveys and further methodological details can be found in the web appendix. The Ipsos MORI tabular data can be found on its website4. Fourth, the manuscript was peer-reviewed by a reviewer with lived experience of a mental health issue. We acknowledge the limitations of our surveys, including the representativeness of the MQ sample, the short timescale for input and the representativeness of online populations. We also acknowledge the limited evidence gathering and opportunity for wider consultation of people with lived experience. However, combined, these four mechanisms of collecting input from people with lived experience provide important insight into people’s concerns about the impact of COVID-19 on mental health and coping strategies within the very limited timeframe.

A living systematic map5 is tracking emerging empirical studies, systematic reviews, and modelling on COVID-19. As of 1st April 2020, 643 were records identified in the databases MEDLINE and Embase. Only 10 of these were on mental health impacts of the pandemic6–15.

**2. Psychology and individual factors: researching the impact of COVID-19 on mental health**

In this section, we focus on the psychological and individual processes in COVID-19, such as cognition, emotion and behaviour, which affect mental health. Two areas that require urgent research prioritisation are:

1. **What is the impact of COVID-19 on risk of anxiety, depression, self-harm, and suicide, and other mental health issues?**

While a rise in anxiety symptoms and coping responses to stress are expected during these extraordinary circumstances, there is a risk that prevalence of clinically-relevant levels of anxiety, depression and other harmful behaviours, such as suicide and self-harm, will increase. It is important to note, however, that a rise in suicide is not inevitable especially with national mitigation efforts16.

The potential fallout of an economic downturn on mental health is likely to be profound on those directly affected as well as on their caregivers. The SARS epidemic was associated with a 30% increase in suicide among those aged 65 and older; around 50% of recovered patients remained anxious; and 29% of health care workers experienced probable emotional distress 17–19. Patients who survived severe and life-threatening illness were at risk of post-traumatic stress disorder and depression18,19. Many of the anticipated consequences of quarantine13 and associated social/physical distancing measures are themselves key risk factors for mental health issues. These include suicide and self-harm, alcohol and substance abuse, gambling, domestic and child abuse, as well as psychosocial risks, such as social disconnection, lack of meaning or anomie, entrapment, cyberbullying, feeling a burden, financial stress, bereavement, loss, unemployment, homelessness and relationship breakdown20–22.

A major adverse consequence of the COVID-19 pandemic is likely to be increased social isolation and loneliness (as reflected in our surveys), which are strongly associated with anxiety, depression, self-harm and suicide attempts across the lifespan23,24. Tracking loneliness and intervening early are important priorities. Critically, reducing sustained feelings of loneliness is a candidate mechanism to protect against suicide, self-harm and emotional problems25,26. Social isolation and loneliness are distinct and may represent different risk pathways.

To inform management of the pandemic it is vital to understand the socioeconomic impact of the policies used to manage the pandemic, which will inevitably have serious effects on mental health by increasing unemployment, financial insecurity and poverty27,28. Involvement of people with lived experience and rapid qualitative research with diverse people and communities may help to identify ways in which this negative impact might be alleviated. Achieving the right balance between infection control and mitigation of these negative socioeconomic impacts must be considered29.

***Immediate research priorities***

**Monitor and report rates of anxiety, depression, self-harm, suicide, as well as other mental health issues both to understand mechanisms and critically to inform interventions.** This should be across the general population and vulnerable groups, including frontline workers. Monitoring must go beyond NHS record linkage to capture the real incidence in the community as self-harm may become more hidden. We must harness existing datasets and ongoing longitudinal studies, and also establish new cohorts with new ways of recording including detailed psychological factors25,30. Techniques assessing moment to moment changes in psychological risk factors should be embraced .

***Longer-term strategic research programmes***

Given the unique circumstances of COVID-19, data will be vital to determine causal mechanisms associated with poor mental health30,31, including loneliness and entrapment. To optimize effectiveness, psychological treatments need to be mechanistically-informed, that is both causally associated with poor mental health and modifiable by an intervention30. A ‘one-size fits all’ response will not suffice, as the effectiveness of interventions can vary across groups25,32–35. **Digital psychological interventions that are mechanistically informed, alongside better understanding of the buffering effects of social relationships during stressful events, are required in the long-term.** The digital response is crucial36–38, not only because of social isolation measures but also because less than a third of people who die by suicide have been in contact with mental health services in the 12 months before death39. Digital interventions for anxiety, depression, self-harm and suicide include: information provision; connectivity and triage; automated and blended therapeutic interventions, such as apps and online programmes; phone calls and messages to reach those with more limited digital resources (digital poverty)40; suicide risk assessments; chatlines and forums; and technologies that can be used to monitor risk either passively or actively. The digital landscape extends beyond apps and requires an evidence-base. Artificial intelligence driven adaptive trials could help evaluate effectiveness while digital phenotyping could be helpful to ascertain early warning signs for mental ill health41.

Looking beyond digital interventions, as not everyone has access to them (e.g. digital poverty), it is important to ascertain what other mechanistically-based psychological interventions are effective and for whom30,42. Risks and buffers for loneliness should be a focal target in interventions to protect wellbeing. The longer-term consequences of COVID-19 on the young and older generations (and other high risk groups including the frontline workforce, those with existing mental health conditions, and caregivers) are also unknown and must be a priority.

1. **How do individuals build optimal structures for a mentally healthy life that works for them in the wake of COVID-19 and social/physical distancing?**

The optimal structure of a mentally healthy life for individuals in the wake of COVID-19 needs to be mapped out. This will vary as a function of background and individual circumstances. Changes in sleep and lifestyle behaviours influence our mental health and stress response. Understanding the effective, individualized ways of coping in such a situation is of paramount importance43–45. The social and personal resources (e.g. seeing family and getting sufficient sleep) available to individuals can be important resilience-related factors for mitigating mental health difficulties under particularly stressful circumstances46. We need research to foster positive social resources, resilience and altruism.

***Immediate research priorities***

**Understanding how frontline health and social care staff and their families can be supported to optimize coping strategies could mitigate symptoms of stress, and facilitate the implementation of preventative interventions in future**47,48. Under COVID-19 it is important that health and social care workers are supported to stay in work; the personal, social and economic benefits are vast**.** Personalized psychological approaches are likely to be a key component to address complex mental health conditions, coping and prevention30. Given the association between sleep disturbance and mental health49, research on mitigating the impact of such changes on our mental health and stress response is required. Indeed, there is an established relationship between the latter and suicide risk50.

***Longer-term strategic research programmes***

**Develop novel interventions to protect mental wellbeing, including those based on positive mechanistic-based components (i.e. causal, modifiable factors) such as altruism and prosocial behaviour.** This could include increased opportunities to elicit community support51,52; exercise53, social activities54, training in assertiveness and conflict resolution55; and group interventions that provide support through peers56.

The inclusion of altruism in UK Government health messages has likely impacted positively on wellbeing compared to compulsory orders to stay at home47. Key research questions include: What altruism-based psychological interventions can be developed for mental wellbeing derived from theories of altruism and prosocial behaviour? What can be learned from the large-scale roll-out of volunteer-based psychological interventions that will optimise the benefits to individuals and society?

Home working, loss of employment and social/physical distancing have abruptly interrupted many social opportunities important to physical and psychological health. It is important to research the mental health dimension of online life, and investigate how changes in engagement with gaming and online platforms might inform interventions aimed at improving mental health. **We must rapidly learn from successful existing strategies to maintain and build social resources and resilience, as well as promote good mental health, in specific populations moving forward.**

**Table 1. Psychology and individual factors: the impact of COVID-19 on mental health**

|  |  |  |
| --- | --- | --- |
| **Psychology and Individual factors** | **Immediate actions** | **Longer term strategic programmes** |
| **What is the impact of COVID-19 on risk of anxiety, depression, and outcomes such as self-harm and suicide?** | Improve monitoring and reporting of the rates of anxiety, depression, self-harm, suicide as well as other mental health issues  Determine the efficacy of mechanistically-based digital and non-digital interventions and evaluate optimal model(s) of implementation | Determine the mechanisms (e.g. entrapment and loneliness) that explain the rates of anxiety, depression, self-harm and suicide  Understand the role of psychological factors in buffering the effect of social context on mental health issues  Ascertain the longer-term consequences on wellbeing of COVID-19 on the young and older generations (and vulnerable groups) |
| **What is the optimal structure for a mentally healthy life in the wake of COVID-19 and social/physical distancing?** | Determine what psychological support is available to support frontline medical and health care staff and their families  Understand the psychological (e.g. coping), physiological (e.g. sleep, nutrition) and structural (e.g. rotas) factors that protect as well as adversely affect mental health | Develop novel interventions to protect mental wellbeing, including those based on positive mechanistic-based components such as altruism and prosocial behaviour and understanding of online life  Understand how we optimize positive social resources and enhance resilience in the face of stress  Establish the effects of altruism on mental health and wellbeing in the wake of COVID-19 |

**3. Social and population factors: the impact of COVID-19 on mental health**

Population level factors, such as the impact of social distancing measures (more recently being re-described as physical distancing57) and other necessary public health measures, affect mental health within a syndemics approach (Table 2). By syndemics we mean intersecting global trends among demographics (e.g. aging, rising inequality) and health conditions (e.g. chronic diseases, obesity) that yield resultant co-morbidities. These interacting health effects and societal forces that fuel them combine to form syndemics, or complex knots of health determinants58. Research priorities around COVID-19 require us to embrace complexity by deploying multidimensional perspectives. Three areas that require urgent research prioritisation are:

1. **What are the mental health consequences of the COVID-19 lock down and social isolation for vulnerable groups, and how can these be mitigated under pandemic conditions?**

We do not yet know the immediate or long term consequences of the COVID-19 lock down and social isolation on mental health. While worries and uncertainties about a pandemic are common, for some they can cause undue distress as well as impairment to social and occupational functioning13,59,60. Across society, a sense of loss can stem from losing direct social contacts, and also range from loss of loved ones, to loss of employment, educational opportunities, recreation, freedoms and supports. Existing evidence suggests some measures taken to control the pandemic may have a disproportionate effect on those most vulnerable (Panel 2).

Vulnerable groups include those with pre-existing mental and/or physical health issues including those with SMI (Severe Mental Illnesses), recovered individuals, and those who become mentally unwell, for example in response to anxiety surrounding the pandemic47,61,62 (Panel 2). Therefore, loss of access to mental health support, alongside loss of positive activities, will increase vulnerability during COVID-19 lockdown. Increased anxiety and depression in response to the outbreak has been widely reported63. Health workers who come in close contact with the virus and are exposed to traumatic events such as death and dying, and also making highly challenging decisions, are particularly at risk of stress responses9.

The pandemic intersects with rising mental health issues in childhood and adolescence2,64,65. Ascertaining and mitigating effects of school closures for youth seeking care is urgent and essential, given school is often a first port of call64,66, considering vulnerabilities such as special educational needs and developmental disorders, and finding therapeutic levers67. For the older population, promoting good mental health is important during self-isolation, which can be compounded by lifestyle restrictions, exacerbated loneliness, co-morbidities such as dementia, feelings of worry and guilt for utilizing resources68. There is an acute need to identify remotely-delivered interventions that support those at risk of abuse69,70.

***Immediate research priorities***

**To reduce mental health issues and boost resilience generally, and in vulnerable groups in particular, a co-ordinating mechanism for pandemic mental health interventions is required for (1) the agile identification of interventions that can be repurposed, alongside identification of gaps which will require bespoke de novo design, and (2) the evaluation and roll-out of bespoke remotely-delivered interventions.** By the term ‘intervention’, we mean interventions of all sorts that make a difference to mental health including population level policy, occupational guidelines, psychological interventions (see earlier section) and so forth.

We need to rapidly gather high quality data to ascertain effects over time. Innovative research is needed to establish ways to mitigate and manage mental health risks and inform interventions under pandemic conditions.

Research to support vulnerable groups needs to consider cross-cutting themes, such as: in the physical absence of schools and clinics, creating methods to provide connectivity and support; rapid innovation in mental health services that can be remotely signposted and delivered, including online clinics and community support; identifying and evaluating means to support those at risk of abuse within the home, including online outreach; and swiftly providing interventions to promote mental well-being in frontline health workers. **By identifying cross-cutting research themes, interventions to help specific vulnerable populations should be leveraged to help other vulnerable groups.**

***Longer-term research priorities***

Health services research must reliably and iteratively inform remotely delivered mental health resources, such as digital clinics to efficiently manage mental health issues in an adaptive and flexible manner71. This requires a co-ordinating mechanism to prioritise and streamline efforts, working with service users to optimise signposting and delivery, as well as defining therapeutic targets that matter from a user perspective (e.g. loss, loneliness). It requires a range of disciplines including psychology, digital science and social sciences72. International collaboration will ensure the necessary research skills and expertise. Research should harness internet-based social media and gaming using existing platforms, and be cognisant of a digital divide that leaves 15% of Britons without internet access73.

Research for population-level interventions will require rapid evolution of approaches, starting with testing whether existing digital interventions can be repurposed, such as physical activity, sleep and stress management programmes, as well as targeted approaches for prevention and treatment of established mental health symptoms (e.g. anxiety and worry74). Tailoring of such universal interventions will need to be informed by experimental and social science, for example for loneliness befriending and physical activity75,76. The effectiveness of arts-based interventions also needs to be assessed77 as other generative activities that boost positive coping and resilience throughout society, from community-based activities to enhance life-skills to exercise outdoors (see lived experience surveys). The effectiveness of all interventions requires rigorous evaluation and implementation to avoid issuing a “plethora of unknown apps”78Interventions at the population level should be repurposed, developed and tested in a virtuous loop to create the necessary evidence base.

1. **What is the impact of repeated media consumption about COVID-19 in traditional and social media on mental health and how can wellbeing be promoted?**

People seek trusted information via the media, which can provide swift, critical guidance regarding the pandemic. Media consumption can be adaptive and positive for mental health. However, reports of infectious diseases often use risk-elevating messages, which can amplify public anxiety79. Social media can be a source of rapidly disseminated misinformation80, amplifying perceptions of risk81. Repeated media exposure to information about an infectious disease particularly can exacerbate stress responses, amplify worry and impair functioning82. Anxiety and uncertainty can drive additional media consumption and further distress, creating a cycle that can be difficult to break83. Media-fuelled distress can promote behaviours that negatively impact the healthcare system (e.g. visits to emergency departments, hoarding of face masks), with downstream mental and physical health consequences84.

***Immediate research priorities***

**There is an urgent need to better understand the role of repeated media consumption around COVID-19 in amplifying distress and mental ill-health in various groups, as well as the optimal patterns of consumption to promote wellbeing.** Research is needed to inform future approaches including strategies to: help individuals to stay informed by authoritative sources; prevent over-exposure to media; and mitigate and help manage the impact of viewing images with traumatic content.

***Longer-term research priorities***

**Research should inform evidence-based guidelines for media around pandemic reporting**, for example clearly identifying authoritative sources, limiting graphic footage and encouraging social media companies to flag or correct disinformation and rumours. Research should help develop **strategies to mitigate individuals’ risk of exposure to misinformation and amplification of anxiety**, for example by minimizing sharing of misinformation and strategies for managing the emotional consequences. Adaptive and positive uses of traditional and social media such as influencers should be understood and harnessed. Knowing the impact of pandemic media on various vulnerable groups, such as at risk children, is critical.

1. **What are the best methods for promoting successful adherence to behavioural advice about COVID-19 whilst enabling mental wellbeing and minimising distress?**

Behavioural change – such as the three personal protective behaviours of handwashing, not touching the T-zone and tissue use, and social/physical distancing required to control the pandemic – necessitates ensuring people know what to do, are motivated to do it and have the skills and opportunity to enact the changed behaviours85,86. Messaging is key for good knowledge86, but public health messaging needs to draw on behavioural science if it is to be effective and avoid unintended consequences. We know that the more concerned people are in pandemics, the more likely they are to adhere to advice87. Increasing concern, however, may heighten distress, which could undermine adherence or exacerbate existing mental health issues. Anxiety can be fuelled by uncertainty, and also by fears of risk of harm to self or others. For example, feelings of paranoia88  can be heavily influenced by anxiety, while symptoms of OCD89 can be associated with fear of contagion and rigid handwashing90. Increasing people’s confidence and clarity in what they need to do fosters adherence to health behaviours91, and can help people to manage psychological distress.

***Immediate action***

**Research on COVID-19 health messaging is urgently required to both optimise health behaviour change, and reduce unintended mental health issues, which will be required in the event of a second wave of infection**. Research should prioritise message content, format and delivery modes and behavioural change alongside risk communication, and consider how this may need to vary for diverse groups. A virtuous cycle which tracks perceptions of and responses to public health messages during this pandemic will enable iterative improvements. It must be informed by mental health science3 to close the gap, for example, between effective behaviour messages and maladaptive consequences.

***Longer-term research priorities***

**It will be vital to create an evidence base of lessons learned to plan for future pandemics.** That is, detailing how to foster a rapid and coordinated response regarding health messaging from governments92 and simultaneously to develop effective systems embedded in communities to reach out and access the most vulnerable groups in our society,including: 1) how to motivate and enable people to prepare psychologically and plan practically for possible future scenarios; and 2) how to promote people’s care and concern for others, fostering a sense of collective solidarity and altruism. The optimal messaging should be tailored (including digitally) to different social groups to connect diverse segments of the population to appropriate mental health information resources.

**Table 2. Social and population factors: the impact of COVID-19 on mental health**

|  |  |  |
| --- | --- | --- |
| **Social and group factors** | **Immediate action** | **Longer term programmes** |
| **What are the mental health consequences of the COVID-19 lock down and social isolation for vulnerable groups, and how can these be mitigated under pandemic conditions?** | Determine best ways of signposting and delivering mental health services for vulnerable groups, including online clinics and community support. Identify and evaluate outreach means to support those at *risk of abuse* within the home.  Ascertain which evidence-based interventions can be rapidly repurposed at scale for the current pandemic, and identify gaps requiring bespoke remotely-delivered interventions to boost resilience and reduce mental health issues.  Swiftly provide interventions to promote mental well-being in frontline health workers exposed to stress and trauma that can be delivered now and at scale. | Based on gaps identified, design bespoke approaches for population-level interventions targeted at (a) prevention and treatment of mental health symptoms (e.g. anxiety) and (b) boosting coping and resilience (e.g. exercise).  Innovation for novel universal interventions on new mechanistically-based targets from experimental and social sciences (e.g. for loneliness befriending; gaming initiatives) that can help mental health.  Assess the effectiveness of arts-based and life-skills based interventions and other generative activities including exercise outdoors. |
| **What is the impact of repeated media consumption about COVID-19 in traditional and social media on mental health and how can wellbeing be promoted?** | Understand the role of repeated media consumption in amplifying distress and anxiety, as well as optimal patterns of consumption for wellbeing.  Develop strategies to prevent over-exposure to anxiety-provoking media; including how to encourage diverse populations to stay informed by authoritative sources they trust. Mitigate and manage the impact of viewing distressing footage.  Mitigate and manage the impact of viewing distressing footage. | Inform evidence-based media policy around pandemic reporting (e.g. clearly identify authoritative sources, encourage companies to correct disinformation, traumatic footage).  Mitigate individuals’ risk of misinformation (e.g. improve health literacy and critical thinking skills, minimize sharing of misinformation).  Understand and harness positive uses of traditional media, online gaming and social media platforms. |
| **What are the best methods for promoting successful adherence to behavioural advice about COVID-19 whilst enabling mental wellbeing and minimising distress?** | Understand how health messaging can optimise behaviour change, and reduce unintended mental health issues.  Track perceptions of and responses to public health messages to allow iterative improvements, informed by mental health science. | Synthesise evidence base of lessons learned for future pandemics, tailored to groups as required.  Motivate and enable people to prepare psychologically and plan practically for possible future scenarios.  Understand the facilitators and barriers for activities that promote good mental health (such as exercise).  Promote people’s care and concern for others, fostering collective solidarity and altruism. |

**Panel 2: Populations of interest, including vulnerable groups**

**Whilst the whole population is affected by the COVID-19 pandemic different sections of the population will experience it differently** – for example:

* **Children, young people and families:** impacts of school closure particularly related to exposure to substance misuse, gambling, domestic violence and child maltreatment, lack of free school meals, accommodation and overcrowding, parental employment, change/disruption of social networks.
* **Older adults and those with multi-morbidities:** isolation, loneliness, end of life care and bereavement, the digital divide.
* **People with existing mental health issues, including those with SMI:** relapse, disruptions to services, isolation, pandemic-related information and behaviours exacerbating symptoms, changes in Mental Health Act.
* **Frontline healthcare workforce:** fears of contamination, moral injury, disruption of normal supportive structures, work stress, retention, enhanced confidence/skills.
* **Excluded groups:** e.g. prisoners, the homeless, refugees.
* **Society**: increased health inequalities, increased foodbank use, increased social cohesion/communitarianism, increased race-based attacks/trauma; rural communities.
* **People with learning difficulties:** change/disruption to support and routines, isolation, loneliness, risk of abuse.
* **People on low incomes:** job and financial insecurity, cramped housing, limited access to internet and technology.

**4. Neuroscience: effects of the virus on brain health and mental health**

Almost nothing is yet known with certainty about the impact of SARS-CoV2 infection on the human nervous system. SARS-CoV2 is a zoonotic virus, and we know that about half of recent zoonotic epidemics have been caused by neurotropic viruses that can invade the central nervous system (CNS). The closely related coronaviruses responsible for the severe acute respiratory syndrome (SARS, 2002) and the Middle East respiratory syndrome (MERS, 2012) are biologically neurotropic and clinically neurotoxic, causing mental health and neurological disorders93–95. SARS-CoV2 is genetically almost identical to the SARS-CoV coronavirus, and likely to share its neurotropism and neurotoxicity.

Neurological symptoms of COVID-19 infection are common, diverse, and often severe. In a retrospective study of 214 patients in Wuhan, China, 36% had CNS symptoms or disorders and the subgroup of 88 patients with severe respiratory disease had significantly increased frequency of CNS problems (45%)96. The problems reported include dizziness, headache, loss of smell (anosmia), loss of taste (ageusia), muscle pain and weakness, impaired consciousness, and cerebrovascular complications. Similar reports have begun to emerge from Italy97. Some of these acute neurological presentations could reflect systemic aspects of infection, such as disseminated intravascular coagulation causing strokes, or intense inflammation and hypoxia causing delirium.

SARS-CoV2 infection of the brain could be a major contributor to the core medical syndrome of respiratory distress and failure in COVID-19 patients98. Viral infection of the lung alveoli is the immediate cause of SARS; but viral infection of the brain stem nuclei could disrupt the normal rhythms and homeostatic control of respiration. This idea needs to be rapidly tested98: if brain stem infection does contribute to SARS-severity and ICU-dependency, that could be directly relevant to the immediate COVID-19 crisis in the NHS and other healthcare systems.

In the longer term, SARS-CoV2 could persistently replicate and proliferate in the brain with direct neurotoxic effects and immune-mediated neurotoxic effects. The Spanish flu epidemic of 1918-19 was linked to a spike in incidence of post-encephalitic Parkinsonism 99. Currently, it is not known if SARS-CoV2 infection of the brain could cause mental health or neurodegenerative disorders, immediately or years after the acute respiratory phase of COVID-19 has passed; but immediate action is needed to build the research capacity to test these potentially important biological causes of COVID-19 related mental illness.

**Table 3.** **Neuroscience: effects of the virus on brain health and mental health**

|  |  |
| --- | --- |
| **Immediate actions** | **Strategic research programmes** |
| Build a neuro-psychological database on UK COVID-19 cases (standardised, longitudinally repeated, data at scale; clinically and geographically inclusive) | Understand how SARS-CoV2 might enter and propagate through the brain and how the immune response to SARS-CoV2 infection contributes to mental health and neurological symptoms  Investigate the long-term relationship between SARS-CoV2 infection and post infective fatigue or depressive syndromes  Validate clinical biomarkers of SARS-CoV2 brain infection using MRI and other methods |
| Expand facilities for SARS-CoV2 tissue handling | Develop interventions to interrupt or prevent the adverse biological impacts of COVID-19 on brain function and mental health, including drug repurposing |

***Immediate actions***

**A neuro-psychological database on COVID 19 cases needs to bring together standardised, longitudinally repeated, data at scale** both from the clinic for those needing hospital treatment and by online assessments for patients in isolation at home. Following the progression of clinical symptoms over time will be key to understanding and predicting the effects of infection on the CNS.

**Facilities for SARS-CoV2 tissue handling need to be expanded** to examine human brain tissue post mortem, crucial to understanding the neurotropic and neurotoxic properties of the virus. Facilities equipped to safely handle human (or animal) brain tissue infected with SARS-CoV2 are currently very limited. We recommend building pathology and molecular neuroscience networks to enable brain and other tissue to be collected at autopsy and examined for viral infection and damage. This will require protocols for tissue collection and examination in appropriate laboratory facilities to protect researchers and other staff at all times.

***Longer term research priorities***

**Mechanisms by which SARS-CoV2 might enter the brain need to be understood.** There are two likely pathways: neuronal and vascular100. The neuronal pathway used by other coronaviruses101,102 is to invade a specialist sensory receptor in peripheral tissue, travel by axonal transport systems to the brain stem, and propagate between neurons by trans-synaptic mechanisms. We need to know if SARS-CoV2 can follow the same path to infect the human brain and whether it invades nerve cells by “hijacking” angiotension converting enzyme 2 (ACE2)103–105, despite neurons expressing low levels of ACE2106–108. SARS-CoV2 could invade the brain from the blood if circulating particles of the virus were transported across the blood-brain barrier by binding to ACE2 receptors expressed by endothelial cells108, or if infected leucocytes could carry the virus with them as they migrate into the tissues as part of the immune response to infection109. We also need to better understand how the intense systemic immune response to SARS-CoV2 infection impacts mental health and neurological symptoms96,110,111 as well as the mechanisms of immune clearance of SARS-CoV2112,113.

Post infectious fatigue and depressive syndromes have been associated with epidemics, and it seems likely that the same will be true of the current pandemic. Longitudinal studies, especially if commenced before or soon after the start of the current pandemic, will be crucial in establishing the often complex biological pathways between infection and mental health outcomes114–116.

**Candidate biomarkers need to be evaluated** to measure SARS-CoV2 infection of the human brain and brain stem in living patients, including magnetic resonance imaging (MRI – e.g. T2 FLAIR to assess possible inflammation), cerebral blood flow imaging (to measure vascular and metabolic effects), and magnetic resonance spectroscopy to measure neurochemicals and metabolites. 7 Tesla MRI has sufficient spatial resolution to measure functional connectivity between subcortical structures that constitute networks for respiratory control and distress117. Other methods could include sampling CSF or positron emission tomography (PET) to measure brain inflammation; self-reporting or behavioural testing of smell, taste and other cranial or vagal sensory functions; electrophysiological methods to measure brain stem function; and computerised tests of cognitive and emotional processing.

Informed by greater understanding of SARS-CoV2 infection on the nervous system, as well as more accurate biomarkers of brain infection in COVID-19 patients, **interventions need to be developed to interrupt or prevent the adverse biological impacts of COVID-19 on brain function and mental health.** Potential drug targets include putative mechanisms for neuronal invasion, inter-neuronal propagation, and immune clearance by SARS-CoV2. Biological and clinical validation of these or other targets would enable experimental medicine studies or early clinical trials of repurposed drugs. For example, ACE2 inhibitors already licensed for treatment of hypertension, or the serine protease TMPRSS2118, which co-operates with ACE2 to facilitate viral entry into cells, and is blocked by a licensed drug for reflux oesophagitis, have already been advocated as repurposable drugs. There are many other potential candidates for drug repurposing119, which could be a faster route to effective treatment for CNS infection than development of entirely new drugs or vaccines. Partnerships between researchers in academia and industry will be vital.

**5. Infrastructure and opportunities**

Many of the immediate priorities are for **surveillance** of general and specific populations for health impacts, ranging from health behaviours, psychological symptoms, neuropsychiatric disorders and mortality including, but not limited to, suicide. The other immediate priority is to **assemble cohorts** to determine longer term outcomes and provide a resource for nesting intervention studies, as well as a resource of interventions to monitor their effectiveness. We recommend three main routes, which we describe in more detail below. For each of these routes**, there is a need to coordinate existing research infrastructure**  through shared protocols, research measures and data assets, as well as to uphold the highest standards of scientific and ethical review. We urge the mental health science community to combine agility in initiating new or adapting existing research with collective scrutiny and collaboration.

First, administrative data assets principally derived from existing **electronic health records**, with systems in place to interrogate these for research purposes, provide a means of identifying health impacts at scale. Health Data Research UK is coordinating national efforts. Examples include the Clinical Practice Research Database120 (CPRD) and similar primary care databases; the Clinical Record Interactive Search121 (CRIS) and related systems for the interrogation of mental health records; and for general hospital settings, CogStack122 which provides near real-time information from health records, for example to provide feedback on neurological consequences of severe COVID-19123. These systems should be linked between mental health, acute medical and community health service providers to identify patterns and trends both in clinical populations and in individuals with confirmed or suspected COVID-19.

Second, surveillance through **recruitment platforms and existing cohorts** has the benefit of embedding research on COVID-19 into studies where participants’ mental or cognitive health has previously been ascertained. Existing cohorts or data platforms that can be rapidly deployed for COVID-19 research are likely to be particularly valuable. Examples include the NIHR National Bioresource, a platform which already includes clinical data on participants and DNA, and could be deployed for rapid characterization of mental health and neurological symptoms. UK Biobank has successfully conducted a web-based mental health survey on 160,000 individuals, and the ongoing neuroimaging studies of 100,000 individuals provide an ideal opportunity to image the impact of SARS-Cov-2 infection on the brain/brainstem via a pre- to post-imaging comparison.

Third, **novel population based studies** on mental health and COVID-19 should be established, both using appropriate epidemiologically robust survey methodology for the whole population and specific groups of particular interest (e.g. children and young people, frontline staff in health and social care, and people who have survived severe COVID-19). Priority should be given to assembling representative populations using explicit sampling frames. Finally, many other disciplines will be establishing similar studies and it is vital that the ascertainment of mental health should be embedded wherever possible.

Whether using established or new cohorts, **priority should be given to methods which can ascertain COVID-19 status, symptoms and behaviours in as close to real time as possible** providing a dynamic picture of change in illness status, social circumstances and behaviours. Questions on COVID-19 and mental health symptoms and social stressors can readily be pushed out via smartphones. Passive data from smartphones can also give high temporal resolution to behaviours related to the pandemic. Cohorts should gain permissions for record linkage including serological status when mass testing becomes available, and consent for recruitment into nested sub-studies including randomised trials of interventions.

Patient and public involvement in research is a critical underpinning component to research. Given that the entire population has lived experience of the COVID-19 pandemic, researchers will need to be particularly mindful of consulting and collaborating with patient and public groups that reflect the diverse groups being studied in developing protocols, conducting research and interpreting results (Panel 3).

**Panel 3: Principles of good research practice in COVID-19 research**

**Study design:** Researchers must continue to articulate the patient group or population and the research question under study. *A priori* research questions are crucial. Sample size, sources of bias and study design need to be carefully considered and appropriate to the research questions.

**Ethics:** Research on human participants should maintain high standards of ethical practice, including seeking research ethics committee approval124. Committees now have fast-track procedures to expedite study start up. Ethical considerations for conducting COVID-19 related research have been published125,126.

**Vulnerable groups:** Researchers should recognise the capacity of the pandemic to exacerbate health inequalities within populations, particularly affecting people with established mental health issues (including SMI) and physical disability, those with precarious or no employment or housing, or other forms of social inequality, such as digital poverty40.

**Involvement of patients, people with lived experience and the public:** Researchers should continue to engage and involve their ultimate consumers, patients, people with lived experience, the public and **service providers**, in mutually setting research questions, testing the acceptability of protocols and questionnaires, and the interpretation of results. Researchers should ensure that they discuss their research findings with participants.

**Harmonised data and measures:** There is an obvious need for researchers to use and share, where possible, full study protocols and measures. This will facilitate comparisons between data and projects.

**Open science, reproducibility and data sharing:** The urgency of the research effort should be a strong driver for the principle of reproducible science. The ready availability of analysis code and data is critical to verifying findings and the rapid peer review of study protocols127, prior to data collection, minimises waste and ensures conclusions are empirically sound.

**Interdisciplinary working:** The challenge of COVID-19 pandemic requires imaginative collaborations between disciplines, including but not limited to psychology, psychiatry, neuroscience, virology, intensive care units, and respiratory medicine, among many others. Previous experience with epidemics has shown the “essential role that the humanities and social sciences play in information, reduction of fear and stigma, prevention, screening, treatment adherence, and control policies”128.

**Collaboration and coordination:** Where possible, research protocols should be deployed at scale harnessing existing research infrastructures including the Clinical Research Networks, Biomedical Research Centres, Mental Health Translational Research Collaboration, MQ Data Science group, charities, service user groups and professional bodies. To avoid waste and protect against participant fatigue, it is vital that there is national coordination across research groups. International collaboration and a global perspective will be beneficial.

**6. Call for action**

**Multidisciplinary mental health science research must be central to the international response to the current pandemic,** given the potential impacts on individual and population mental health and its potential impact on the brain function of some of those affected by COVID-19. There are important immediate insights to be gained, which could provide evidence-based guidance on responding to this pandemic, as well as how to promote mental health and wellbeing and safeguard the brain should future waves of infection re-emerge (see Panel 4).

The research priorities across the social, psychological and neuroscientific aspects of this pandemic should be coordinated at a national and international level. **We urge UK research funding agencies to work with researchers, people with lived experience and others to establish a high level co-ordination group to ensure that the mental health science research priorities are addressed swiftly, and that a firm base is established for long term studies.** We need rigorous, peer-reviewed, ethically-approved research co-developed with people with lived experience that can be translated into effective interventions, rather than the current uncoordinated approach with a plethora of underpowered studies and surveys.

**The immediate priority is collecting high quality data** on the mental health and psychological impacts of the COVID-19 pandemic across the whole population and vulnerable groups, and on brain function, cognition and mental health for COVID-19 patients at all clinical stages of infection and illness. These datasets must be brought together **under a national data portal** for rapid access and use.

**There is an urgent need for the discovery, evaluation and refinement of mechanistically-driven interventions to address the psychological, social and neuroscientific aspects of this pandemic.** This includes bespoke psychological interventions to boost resilience and minimize mental health risks across society and in vulnerable groups, and experimental medicine studies to validate clinical biomarkers and repurpose new treatments for the potentially neurotoxic effects of the virus. There is an urgent need for research to address the impact of repeated pandemic related media consumption and to optimise health messaging around COVID-19. Rising to this challenge will require **integration across disciplines and sectors, including industry and health and social care.**

**New funding will be required to meet these priorities, but it can be efficiently leveraged by the UK’s world-leading neuroscience and mental health research infrastructure.** The UK must connect with international funders and researchers to support a global response to the mental health and neurological challenges of this pandemic. These are challenging times, but there is a tremendous opportunity for mental health science to serve society and benefit medicine in the long term.

**Panel 4: Rapid learnings to apply to future infection waves or pandemics**

The outputs of immediate research could help inform responses to future infection waves of pandemics, for example by identifying:

* Mechanisms to support vulnerable groups under pandemic conditions – such as front line health and social care staff and those with pre-existing mental health issues, young people and older adults – including coping strategies and preventative interventions.
* Interventions that reduce mental health issues and boost resilience, including those that can be repurposed.
* Solutions to the impact of repeated media consumption about COVID-19 on the mental wellbeing of the nation to help individuals stay informed by authoritative sources while preventing over-exposure and mitigating the impact of viewing traumatic content.
* Methods for promoting more successful adherence to behavioural advice about COVID-19 while enabling mental wellbeing and minimising distress to inform medical treatment.

**Contributors**

EB, EAH, MH, RCOC, VHP, IT and SW contributed to the literature review, conceptualisation, design and interpretation of surveys, and writing and editing of the manuscript as part of the core advisory group. CC contributed to and coordinated the writing and editing of the manuscript. KC analysed the qualitative data gathered via the stakeholder survey. LA, CB, HC, IE, TF, AJ, IM, SM, AKP, RS, RCS, CMW and LY contributed to the drafting and formulation of the manuscript as part of the expert advisory group. TK, KK and AS contributed the drafting and formulation of the manuscript as part of the expert advisory group and by including lived-experience expertise. All authors approved the final version for submission.

**Declaration of interest**

CB reports grants and personal fees from Acadia pharmaceutical company and Lundbeck, personal fees from Roche, Otsuka, Biogen, Eli Lilly, Novo Nordisk, AARP and Exciva, and grants from Synexus, outside the submitted work.

EAH reports grants from The Lupina Foundation, The OAK Foundation, The Swedish Research Council, outside the submitted work. EAH reports her primary affiliation is Department of Psychology, Uppsala University, Sweden and is also a professor at Division of Psychology, Department for Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. EAH reports serving on the board of trustees of the charity MQ: Transforming Mental Health (UK) as chair of the research committee. She receives no remuneration for these roles. EAH reports serving on the Editorial Advisory Board of The Lancet Psychiatry, and is an Associate Editor of Behavior Research and Therapy. She is the F1000 prime: Clinical Psychology and Psychopathology Section Head and is on the Editorial Board of following journals: Current Opinion in Psychology, Clinical Psychology in Europe, and Cognitive Behaviour Therapy. EAH receives book royalties from Oxford University Press (Imagery and Cognitive Therapy) and Guilford Press (Imagery-Based Cognitive Therapy for Bipolar Disorder and Mood Instability). She receives occasional fees from clinical workshops and conference keynotes. She receives occasional consultancy fees from SBU: Statens beredning för medicinsk och social utvärdering (Swedish agency for health technology assessment and assessment of social services), Sweden.

AKP has been financially supported by UK taxpayers, the UK's Economic and Social Research Council, the British Academy, the Diana Award, the John Fell Fund, the Leverhulme Trust, Barnardo's UK, and the Huo Family Foundation in the past five years. As part of science communication and policy outreach activities, he has served in an unpaid advisory capacity to the Organization for Economic Co-operation and Development, Facebook Inc., Google Inc., and the ParentZone.

IT is a Trustee of MQ, which is a mental health charity dedicated to raise funds to support research into mental health. She is also on the Council for the Medical Research Council of the United Kingdom.

MH reports grants from Innovative Medicines Intiative, outside the submitted work.

CC reports that Academy of Medical Science staff, including herself, and activity costs for this work were supported by a core grant the Academy of Medical Sciences receives annually from the Government Department for Business, Energy & Industrial Strategy for policy, communications and public engagement. She also reports that her husband is an employee of Otsuka Pharmaceutical Europe Limited and is a Trustee of The McPin Foundation.

All other authors declare no competing interests.

**Funding source**

LA is the Mental Health Leadership Fellow for the Economic and Social Research Council.

EB is a National Institute for Health Research (NIHR) Senior Investigator. This paper represents independent research part-funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at Cambridge University Hospital NHS Trust and the University of Cambridge. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

CC indicated that Academy of Medical Science staff, including herself, and activity costs for this work were supported by a core grant the Academy of Medical Sciences receives annually from the Government Department for Business, Energy & Industrial Strategy (BEIS) for policy, communications and public engagement.

MH is funded by the National Institute of Health Research Biomedical Research Centre at the Maudsley and a National Institute of Health Research Senior Investigator Award. This paper represents independent research part-funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. NIHR were not involved in any aspect of the publication and had no role in the decision to submit.

AKP received funding from the Huo Family Foundation.

RS indicated that all research at Great Ormond Street Hospital NHS Foundation Trust and UCL Great Ormond Street Institute of Child Health is made possible by the NIHR Great Ormond Street Hospital Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

LY is an NIHR Senior Investigator and her research programme is partly supported by NIHR Applied Research Collaboration (ARC)-West, NIHR Health Protection Research Unit (HPRU) for Behavioural Science and Evaluation, and the NIHR Southampton Biomedical Research Centre (BRC).

The funding for TK’s salary came solely from his employer, The McPin Foundation.

The views expressed are the views of the authors alone and do not necessarily represent the views of their organisations or funding sources.

**Acknowledgements**

We are grateful to all staff at the Academy of Medical Sciences and MQ for their work in coordinating and supporting this project’s secretariat and communications. Special thanks to Rachel Quinn, Nick Hillier, Helen Munn, Neil Balmer, Angeliki Yiangou, Fern Brookes, Holly Rogers, Claire Bithell, Naomi Clarke, Melanie Etherton, Tom Livermore, Dylan Williams and Daisy Armitage. We also extend our sincere thanks to Katie White, Carolin Oetzmann, Valeria de Angel and Dr Sumithra Velupillai at King’s College London for their tremendous efforts in data analysis, and Dr Beau Gamble at Uppsala University and Dr Seonaid Cleare at University of Glasgow for their support with referencing. We are also grateful to the team at Ipsos MORI for their work on the online omnibus. Special thanks also to everyone who participated in the MQ and Ipsos MORI surveys for sharing their views and personal experiences during challenging times – we are hugely grateful to them for their openness and honesty about mental health and wellbeing. We are grateful to Professor Peter Jones for comments on an earlier draft.

++++

**References**

1 McManus S, Bebbington P, Jenkins R, Brugha T. Mental health and wellbeing in England: Adult Psychiatric Morbidity Survey 2014. Leeds, 2016.

2 Ford T, Vizard T, Sadler K, *et al.* Data Resource Profile: The Mental Health of Children and Young People Surveys (MHCYP). *Int J Epidemiol* 2020. DOI:10.1093/ije/dyz259.

3 Holmes EA, Craske MG, Graybiel AM. Psychological treatments: A call for mental-health science. *Nature* 2014; **511**: 287–9.

4 Ipsos MORI. Covid-19 and mental wellbeing. https://www.ipsos.com/ipsos-mori/en-uk/Covid-19-and-mental-wellbeing (accessed April 7, 2020).

5 Lorenc T, Khouja C, Raine G, *et al.* COVID-19: a living systematic map of the evidence. 2020. http://eppi.ioe.ac.uk/cms/Projects/DepartmentofHealthandSocialCare/Publishedreviews/COVID-19Livingsystematicmapoftheevidence/tabid/3765/Default.aspx (accessed April 5, 2020).

6 Qiu J, Shen B, Zhao M, Wang Z, Xie B, Xu Y. A nationwide survey of psychological distress among Chinese people in the COVID-19 epidemic: implications and policy recommendations. *Gen Psychiatry* 2020; **33**: e100213.

7 Lai J, Ma S, Wang Y, *et al.* Factors associated with mental health outcomes among health care workers exposed to coronavirus disease 2019. *JAMA Netw Open* 2020; **3**: e203976.

8 Wang C, Pan R, Wan X, *et al.* Immediate psychological responses and associated factors during the initial stage of the 2019 coronavirus disease (COVID-19) epidemic among the general population in China. *Int J Environ Res Public Health* 2020; **17**: 1–25.

9 Liu S, Yang L, Zhang C, *et al.* Online mental health services in China during the COVID-19 outbreak. *Lancet Psychiatry* 2020; **7**: e17–8.

10 Bo H-X, Li W, Yang Y, *et al.* Posttraumatic stress symptoms and attitude toward crisis mental health services among clinically stable patients with COVID-19 in China (accepted). *Psychol Med* 2020; published online March 27. DOI:10.1017/S0033291720000999.

11 Xiao H, Zhang Y, Kong D, Li S, Yang N. The effects of social support on sleep quality of medical staff treating patients with coronavirus disease 2019 (COVID-19) in January and February 2020 in China. *Med Sci Monit* 2020; **26**: e923549.

12 Li S, Wang Y, Xue J, Zhao N, Zhu T. The Impact of COVID-19 Epidemic Declaration on Psychological Consequences: A Study on Active Weibo Users. *Int J Environ Res Public Health* 2020; **17**: 2032.

13 Brooks SK, Webster RK, Smith LE, *et al.* The psychological impact of quarantine and how to reduce it: rapid review of the evidence. *Lancet* 2020; **395**: 912–20.

14 Li Z, Ge J, Yang M, *et al.* Vicarious traumatization in the general public, members, and non-members of medical teams aiding in COVID-19 control. *Brain Behav Immun* 2020; published online March 10. DOI:10.1016/j.bbi.2020.03.007.

15 Huang JZ, Han MF, Luo TD, Ren AK, Zhou XP. Mental health survey of 230 medical staff in a tertiary infectious disease hospital for COVID-19. *Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi* 2020; **38**: E001.

16 Gunnell D, Appleby L, Arensman E, *et al.* Suicide risk and prevention during the COVID19 pandemic (submitted). *Lancet Psychiatry*.

17 Yip PS. PSF, Cheung Y. T, Chau P. H, Law Y. W. The impact of epidemic outbreak: the case of severe acute respiratory syndrome (SARS) and suicide among older adults in Hong Kong. *Crisis* 2010; **31**: 86–92.

18 Tsang HW, Scudds RJ, Chan EY. Psychosocial impact of SARS. *Emerg Infect Dis* 2004; **10**: 1326–7.

19 Nickell LA, Crighton EJ, Tracy CS, *et al.* Psychosocial effects of SARS on hospital staff: survey of a large tertiary care institution. *CMAJ* 2004; **170**: 793–8.

20 O’Connor RC, Nock MK. The psychology of suicidal behaviour. *Lancet Psychiatry* 2014; **1**: 73–85.

21 John A, Glendenning AC, Marchant A, *et al.* Self-harm, suicidal behaviours, and cyberbullying in children and young people: Systematic review. *J Med Internet Res* 2018; **20**: e129.

22 Turecki G, Brent DA, Gunnell D, *et al.* Suicide and suicide risk. *Nat Rev Dis Prim* 2019; **5**: 1–22.

23 Elovainio M, Hakulinen C, Pulkki-Råback L, *et al.* Contribution of risk factors to excess mortality in isolated and lonely individuals: an analysis of data from the UK Biobank cohort study. *Lancet Public Heal* 2017; **2**: e260–6.

24 Matthews T, Danese A, Caspi A, *et al.* Lonely young adults in modern Britain: Findings from an epidemiological cohort study. *Psychol Med* 2018; **49**: 268–77.

25 O’Connor RC, Kirtley OJ. The integrated motivational-volitional model of suicidal behaviour. *Philos Trans R Soc B Biol Sci* 2018; **373**: 20170268.

26 Stack S. Suicide: media impacts in war and peace, 1910-1920. *Suicide Life‐Threatening Behav* 1988; **18**: 342–57.

27 Barr B, Taylor-Robinson D, Scott-Samuel A, McKee M, Stuckler D. Suicides associated with the 2008-10 economic recession in England: Time trend analysis. *BMJ* 2012; **345**: 1–7.

28 Frasquilho D, Matos MG, Salonna F, *et al.* Mental health outcomes in times of economic recession: A systematic literature review Health behavior, health promotion and society. *BMC Public Health* 2016; **16**: 1–40.

29 Prieto L, Sacristán JA. Problems and solutions in calculating quality-adjusted life years (QALYs). *Health Qual Life Outcomes* 2003; **1**: 1–8.

30 Holmes EA, Ghaderi A, Harmer CJ, *et al.* The Lancet Psychiatry Commission on psychological treatments research in tomorrow’s science. *The Lancet Psychiatry* 2018; **5**: 237–86.

31 Kazdin AE. Mediators and Mechanisms of Change in Psychotherapy Research. *Annu Rev Clin Psychol* 2007; **3**: 1–27.

32 Carl E, Witcraft SM, Kauffman BY, *et al.* Psychological and pharmacological treatments for generalized anxiety disorder (GAD): a meta-analysis of randomized controlled trials. *Cogn Behav Ther* 2020; **49**: 1–21.

33 Hawton K, Witt KG, Salisbury TLT, *et al.* Psychosocial interventions following self-harm in adults: a systematic review and meta-analysis. *The Lancet Psychiatry* 2016; **3**: 740–50.

34 Cuijpers P, Cristea IA, Karyotaki E, Reijnders M, Hollon SD. Component studies of psychological treatments of adult depression: A systematic review and meta-analysis. *Psychother Res* 2019; **29**: 15–29.

35 Spinhoven P, Cuijpers P, Hollon S. Cognitive-behavioural therapy and personalized treatment:An introduction to the special issue. *Behav Res Ther* 2020. DOI:10.1016/j.brat.2020.103595.

36 Torok M, Han J, Baker S, *et al.* Suicide prevention using self-guided digital interventions: a systematic review and meta-analysis of randomised controlled trials. *Lancet Digit Heal* 2020; **2**: e25–36.

37 Garrido S, Millington C, Cheers D, *et al.* What works and what doesn’t work? A systematic review of digital mental health interventions for depression and anxiety in young people. *Front Psychiatry* 2019; **10**: 19.

38 Lattie EG, Adkins EC, Winquist N, Stiles-Shields C, Wafford QE, Graham AK. Digital mental health interventions for depression, anxiety and enhancement of psychological well-being among college students: Systematic review. *J Med Internet Res* 2019; **21**: e12869.

39 National Confidential Inquiry into Suicide and Homicide by People with Mental Illness. 2017. www.hqip.org.www.bbmh.manchester.ac.uk/cmhs (accessed April 1, 2020).

40 Greer B, Robotham D, Simblett S, Curtis H, Griffiths H, Wykes T. Digital Exclusion Among Mental Health Service Users: Qualitative Investigation. *J Med Internet Res* 2019; **21**: e11696.

41 Huckvale K, Venkatesh S, Christensen H. Toward clinical digital phenotyping: a timely opportunity to consider purpose, quality, and safety. *npj Digit Med* 2019; published online Sept 6. DOI:10.1038/s41746-019-0166-1.

42 O’Connor RC, Portzky G. Looking to the future: a synthesis of new developments and challenges in suicide research and prevention. *Front Psychol* 2018; **9**: 1–14.

43 Lazarus RS, Folkman S. Stress, appraisal, and coping. Springer Publishing Company, 1984.

44 Folkman S. Stress, Health, and Coping: Synthesis, Commentary, and Future Directions. In: Folkman S, ed. The Oxford Handbook of Stress, Health, and Coping. Oxford University Press, 2010. https://doi.org/10.1093/oxfordhb/9780195375343.013.0022 (accessed March 30, 2020).

45 Folkman S, Moskowitz JT. Coping: pitfalls and promise. *Annu Rev Psychol* 2004; **55**: 745–74.

46 Sehmi R, Maughan B, Matthews T, Arseneault L. No man is an island: social resources, stress and mental health at mid-life. *Br J Psychiatry* 2019. DOI:10.1192/bjp.2019.25.

47 Brooks SK, Webster RK, Smith LE, *et al.* The psychological impact of quarantine and how to reduce it: rapid review of the evidence. *Lancet* 2020; **395**: 912–20.

48 Duan L, Zhu G. Psychological interventions for people affected by the COVID-19 epidemic. *Lancet* 2020; **7**: 300–2.

49 Alvaro PK, Roberts RM, Harris JK. A systematic review assessing bidirectionality between sleep disturbances, anxiety, and depression. *Sleep* 2013; **36**: 1059–68.

50 Connor DBO, Gartland N, Connor RCO. Stress, cortisol and suicide risk (in press). *Int Rev Neurobiol* 2020. DOI:10.1016/bs.irn.2019.11.006.

51 Dawson KS, Bryant RA, Harper M, *et al.* Problem Management Plus (PM+): a WHO transdiagnostic psychological intervention for common mental health problems. *World Psychiatry* 2015; **14**: 354–7.

52 Hogan BE, Linden W, Najarian B. Social support interventions: do they work? *Clin Psychol Rev* 2002; **22**: 381–440.

53 Ashdown-Franks G, Firth J, Carney R, *et al.* Exercise as medicine for mental and substance use disorders: A meta-review of the benefits for neuropsychiatric and cognitive outcomes. *Sport Med* 2020; **50**: 151–70.

54 Solomonov N, Bress JN, Sirey JA, *et al.* Engagement in socially and interpersonally rewarding activities as a predictor of outcome in “Engage” behavioral activation therapy for late-life depression. *Am J Geriatr Psychiatry* 2019; **27**: 571–8.

55 Meunier S, Roberge C, Coulombe S, Houle J. Feeling better at work! Mental health self-management strategies for workers with depressive and anxiety symptoms. *J Affect Disord* 2019; **254**: 7–14.

56 Taubman D.S, Parikh S.V, Christensen H, Scott J. Using school-based interventions for depression education and prevention. In: Javed A, Fountoulakis K, eds. Advances in Psychiatry. Springer, 2019: 1–32.

57 Wasserman D, Rutger van der G, Wise J. Terms ‘physical distancing’ and ‘emotional closeness’ should be used and not ‘social distancing’ when defeating the Covid-19 pandemic. Sci. eLetters. 2020. https://science.sciencemag.org/content/367/6484/1282/tab-e-letters (accessed April 3, 2020).

58 Swinburn BA, Kraak VI, Allender S, *et al.* The Global Syndemic of Obesity, Undernutrition, and Climate Change: The Lancet Commission report. *Lancet* 2019; **393**: 791–846.

59 Rubin GJ, Potts HWW, Michie S. The impact of communications about swine flu (influenza A HINIv) on public responses to the outbreak: Results from 36 national telephone surveys in the UK. *Health Technol Assess (Rockv)* 2010; **14**: 183–266.

60 Lau JTF, Griffiths S, Choi KC, Tsui HY. Avoidance behaviors and negative psychological responses in the general population in the initial stage of the H1N1 pandemic in Hong Kong. *BMC Infect Dis* 2010; **10**: 1–13.

61 Wang J, Lloyd-Evans B, Giacco D, *et al.* Social isolation in mental health: a conceptual and methodological review. *Soc Psychiatry Psychiatr Epidemiol* 2017; **52**: 1451–61.

62 Cacioppo JT, Hughes ME, Waite LJ, Hawkley LC, Thisted RA. Loneliness as a specific risk factor for depressive symptoms: Cross-sectional and longitudinal analyses. *Psychol Aging* 2006; **21**: 140–51.

63 Lv Y, Zhang Z, Zeng W, Li J, Wang X, Luo L. Anxiety and depression survey of Chinese medical staff before and during COVID-19 defense. *Lancet Prepr* 2020; published online March 30. DOI:10.2139/ssrn.3551350.

64 Collishaw S. Annual Research Review: Secular trends in child and adolescent mental health. *J Child Psychol Psychiatry* 2015; **56**: 370–93.

65 Sellers R, Warne N, Pickles A, Maughan B, Thapar A, Collishaw S. Cross‐cohort change in adolescent outcomes for children with mental health problems. *J Child Psychol Psychiatry* 2019; **60**: 813–21.

66 Fazel M, Karunakara U, Newnham EA. Detention, denial, and death: migration hazards for refugee children. *Lancet Glob Heal* 2014; **2**: e313–4.

67 Schoneveld EA, Lichtwarck-Aschoff A, Granic I. Preventing childhood anxiety disorders: is an applied game as effective as a cognitive behavioral therapy-based program? *Prev Sci* 2018; **19**: 220–32.

68 Armitage R, Nellums LB. COVID-19 and the consequences of isolating the elderly. *Lancet Public Heal* 2020; published online March 19. DOI:10.1016/S2468-2667(20)30061-X.

69 Robotham D, Sweeney A, Perôt C. Survivors’ priority themes and questions for research. 2019. https://www.vamhn.co.uk/uploads/1/2/2/7/122741688/consultation\_report\_on\_website.pdf (accessed March 30, 2020).

70 Sweeney, A, Beresford, P, Nettle, M, Faulkner, A, Rose D. This Is Survivor Research. PCCS Books, 2009 https://www.researchgate.net/publication/257606229\_This\_Is\_Survivor\_Research (accessed March 30, 2020).

71 Wind TR, Rijkeboer M, Andersson G, Riper H. The COVID-19 pandemic: The ‘black swan’ for mental health care and a turning point for e-health. *Internet Interv* 2020; published online March 19. DOI:10.1016/j.invent.2020.100317.

72 Milton AL, Holmes EA. Of mice and mental health: facilitating dialogue and seeing further. *Philos Trans R Soc B* 2018; **373**: 20170022.

73 Blank G, Dutton WH, Lefkowitz J. OxIS 2019: Digital Divides in Britain are Narrowing but Deepening. 2020. https://ssrn.com/abstract=3522083 (accessed April 4, 2020).

74 Hirsch CR, Krahé C, Whyte J, *et al.* Interpretation Training to Target Repetitive Negative Thinking in Generalized Anxiety Disorder and Depression. *J Consult Clin Psychol* 2018; **86**: 1017–30.

75 Holt-Lunstad J, Robles TF, Sbarra DA, Julianne Holt-Lunstad N. Advancing Social Connection as a Public Health Priority in the United States. *Am Psychol* 2017; **72**: 517–30.

76 Agency for Healthcare Research and Quality. Addressing social isolation To improve the health of older adults: A rapid review. 2019 www.ahrq.gov (accessed March 30, 2020).

77 Fancourt D, Finn S. What is the evidence on the role of the arts in improving health and well-being? A scoping review. Copenhagen: WHO Regional Office for Europe, 2019.

78 Anthes E. Pocket psychiatry: mobile mental-health apps have exploded onto the market, but few have been thoroughly tested. *Nature* 2016; **532**: 20–3.

79 Sell TK, Boddie C, McGinty EE, *et al.* Media messages and perception of risk for Ebola virus infection, United States. *Emerg Infect Dis* 2017; **23**: 108–11.

80 Wang Y, McKee M, Torbica A, Stuckler D. Systematic Literature Review on the Spread of Health-related Misinformation on Social Media. *Soc Sci Med* 2019; **240**: 112552.

81 Ng YJ, Yang ZJ, Vishwanath A. To fear or not to fear? Applying the social amplification of risk framework on two environmental health risks in Singapore. *J Risk Res* 2018; **21**: 1487–501.

82 Thompson RR, Garfin DR, Holman EA, Silver RC. Distress, Worry, and Functioning Following a Global Health Crisis: A National Study of Americans’ Responses to Ebola. *Clin Psychol Sci* 2017; **5**: 513–21.

83 Thompson RR, Jones NM, Holman EA, Silver RC. Media exposure to mass violence events can fuel a cycle of distress. *Sci Adv* 2019; **5**: eaav3502.

84 Garfin DR, Silver RC, Holman EA. The novel coronavirus (COVID-2019) outbreak: Amplification of public health consequences by media exposure. *Heal Psychol* 2020; published online March 23. DOI:10.1037/hea0000875.

85 Michie, West, Amlot R. Slowing down the covid-19 outbreak: changing behaviour by understanding it - The BMJ. BMJ Opin. 2020. https://blogs.bmj.com/bmj/2020/03/11/slowing-down-the-covid-19-outbreak-changing-behaviour-by-understanding-it/ (accessed March 30, 2020).

86 Michie S, van Stralen MM, West R. The behaviour change wheel: A new method for characterising and designing behaviour change interventions. *Implement Sci* 2011; **6**. DOI:10.1186/1748-5908-6-42.

87 Rubin GJ, Potts HWW, Michie S. The impact of communications about swine flu (influenza A H1N1v) on public responses to the outbreak: results from 36 national telephone surveys in the UK. *Health Technol Assess (Rockv)* 2010; **14**: 183–266.

88 Freeman D, Garety PA, Bebbington PE, *et al.* Psychological investigation of the structure of paranoia. *Br J Psychiatry* 2005; **186**.

89 Torres, A. R., Fontenelle, L. F., Shavitt, R. G., Hoexter, M. Q., Pittenger, C., Miguel EC. Epidemiology, comorbidity, and burden of OCD. In: Pittenger C, ed. Obsessive-compulsive Disorder: Phenomenology, Pathophysiology, and Treatment. Oxford University Press, 2017.

90 Abramowitz JS, McKay D, Storch EA. The Wiley Handbook of Obsessive Compulsive Disorders. Chichester, UK: John Wiley & Sons, Ltd, 2017 DOI:10.1002/9781118890233.

91 Peters GJY, Ruiter RAC, Kok G. Threatening communication: A critical re-analysis and a revised meta-analytic test of fear appeal theory. *Health Psychol Rev* 2013; **7**: S8–31.

92 Public Health England. A Century of Public Health Marketing: Enduring public health challenges and revolutions in communication. 2017. https://publichealthengland.exposure.co/100-years-of-public-health-marketing (accessed April 7, 2020).

93 Li YC, Bai WZ, Hirano N, Hayashida T, Hashikawa T. Coronavirus infection of rat dorsal root ganglia: Ultrastructural characterization of viral replication, transfer, and the early response of satellite cells. *Virus Res* 2012; **163**: 628–35.

94 Xu J, Zhong S, Liu J, *et al.* Detection of severe acute respiratory syndrome coronavirus in the brain: potential role of the chemokine Mig in pathogenesis. *Clin Infect Dis* 2005; **41**: 1089–96.

95 Li K, Wohlford-Lenane C, Perlman S, *et al.* Middle east respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4. *J Infect Dis* 2016; **213**: 712–22.

96 Mao L, Wang M, Chen S, *et al.* Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study. *medRxiv* 2020; published online Feb 25. DOI:10.1101/2020.02.22.20026500.

97 Talan J. COVID-19: Neurologists in Italy to colleagues in US: Look for poorly-defined neurologic conditions in patients with the coronavirus. NeurologyToday. 2020. https://journals.lww.com/neurotodayonline/blog/breakingnews/pages/post.aspx?PostID=920 (accessed March 27, 2020).

98 Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may be at least partially responsible for the respiratory failure of COVID-19 patients. *J Med Virol* 2020; published online Feb 27. DOI:10.1002/jmv.25728.

99 McCall S, Vilensky JA, Gilman S, Taubenberger JK. The relationship between encephalitis lethargica and influenza: a critical analysis. *J Neurovirol* 2008; **14**: 177–85.

100 Desforges M, Le Coupanec A, Dubeau P, *et al.* Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? *Viruses* 2019; **12**: 1–28.

101 Dubé M, Le Coupanec A, Wong AHM, Rini JM, Desforges M, Talbot PJ. Axonal transport enables neuron-to-neuron propagation of human coronavirus OC43. *J Virol* 2018; **92**: e00404-18.

102 Andries K, Pensaert M. Immunofluorescence studies on the pathogenesis of hemagglutinating encephalomyelitis virus infection in pigs after oronasal inoculation. *Am J Vet Res* 1980; **41**: 1372–8.

103 Wrapp D, Wang N, Corbett KS, *et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science (80- )* 2020; **367**: 1260–3.

104 Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. *Intensive Care Med* 2020; **46**: 586–90.

105 Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S. Severe Acute Respiratory Syndrome Coronavirus Infection Causes Neuronal Death in the Absence of Encephalitis in Mice Transgenic for Human ACE2. *J Virol* 2008; **82**: 7264–75.

106 Brann DH, Tsukahara T, Weinreb C, Logan DW, Datta SR. Non-neural expression of SARS-CoV-2 entry genes in the olfactory epithelium suggests mechanisms underlying anosmia in COVID-19 patients. *bioRxiv Prepr*; published online March. DOI:10.1101/2020.03.25.009084.

107 Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host–virus interaction, and proposed neurotropic mechanisms. *ACS Chem Neurosci* 2020; **11**: 995–8.

108 Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J Pathol* 2004; **203**: 631–7.

109 Desforges M, Miletti TC, Gagnon M, Talbot PJ. Activation of human monocytes after infection by human coronavirus 229E. *Virus Res* 2007; **130**: 228–40.

110 Chen G, Wu D, Guo W, *et al.* Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. *J Clin Invest* 2020; published online March 27. DOI:10.1172/JCI137244.

111 Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. *Nat Rev Neurosci* 2008; **9**: 46–56.

112 Arabi YM, Harthi A, Hussein J, *et al.* Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV). *Infection* 2015; **43**: 495–501.

113 Bender SJ, Weiss SR. Pathogenesis of murine coronavirus in the central nervous system. *J Neuroimmune Pharmacol* 2010; **5**: 336–54.

114 Wessely S. History of postviral fatigue syndrome. *Br Med Bull* 1991; **47**: 919–41.

115 White PD, Thomas JM, Amess J, *et al.* Incidence, risk and prognosis of acute and chronic fatigue syndromes and psychiatric disorders after glandular fever. *Br J Psychiatry* 1998; **173**: 475–81.

116 Wessely S, Chalder T, Hirsch S, Pawlikowska T, Wallace P, Wright DJM. Postinfectious fatigue: prospective cohort study in primary care. *Lancet* 1995; **345**: 1333–8.

117 Faull OK, Jenkinson M, Clare S, Pattinson KTS. Functional subdivision of the human periaqueductal grey in respiratory control using 7 tesla fMRI. *Neuroimage* 2015; **113**: 356–64.

118 Hoffmann M, Kleine-Weber H, Schroeder S, *et al.* SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell* 2020; **181**: 1–10.

119 Nabirotchkin S, Peluffo AE, Bouaziz J, Cohen D. Focusing on the unfolded protein response and autophagy related pathways to reposition common approved drugs against COVID-19. *Preprints* 2020; published online March 20. DOI:10.20944/preprints202003.0302.v1.

120 Herrett E, Gallagher AM, Bhaskaran K, *et al.* Data Resource Profile: Clinical Practice Research Datalink (CPRD). *Int J Epidemiol* 2015; **44**: 827–36.

121 Stewart R, Soremekun M, Perera G, *et al.* The South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) case register: Development and descriptive data. *BMC Psychiatry* 2009; **9**: 1–12.

122 Jackson R, Kartoglu I, Stringer C, *et al.* CogStack - Experiences of deploying integrated information retrieval and extraction services in a large National Health Service Foundation Trust hospital. *BMC Med Inform Decis Mak* 2018; **18**: 1–13.

123 Needham EJ, Chou SHY, Coles AJ, Menon DK. Neurological implications of COVID-19 infections (submitted). *Lancet Neurol*.

124 Gostin OL, Bayer R, Fairchild AL. Ethical and Legal Challenges Posed by Severe Acute Respiratory Syndrome. *JAMA* 2003; **290**: 3229–37.

125 Townsend E, Nielsen E, Allister A, Cassidy SA. Key ethical questions for research during the COVID-19 Pandemic. *Lancet Psychiatry* 2020.

126 Nuffield Council on Bioethics. Rapid policy briefing: Ethical considerations in responding to the COVID-19 pandemic. 2020. https://www.nuffieldbioethics.org/publications/covid-19 (accessed April 7, 2020).

127 Chambers C. What’s next for registered reports? *Nature* 2019; **573**: 187–9.

128 Raguin G, Girard PM. Toward a global health approach: Lessons from the HIV and Ebola epidemics. *Global Health* 2018; **14**: 114.